Breaking News Instant updates and real-time market news.

SAGE

Sage Therapeutics

$126.62

-10.64 (-7.75%)

06:46
11/06/18
11/06
06:46
11/06/18
06:46

Sage Therapeutics reports Q3 EPS ($2.63), consensus ($2.42)

Cash, cash equivalents, and marketable securities as of September 30 were $1.0B, compared with $518.8M at December 31, 2017. The increase was primarily due to net proceeds of $631.2M from Sage's follow-on public offering completed in February, and an upfront milestone payment from Shionogi & Co. related to the strategic collaboration that was entered in June.

  • 06

    Nov

  • 06

    Nov

  • 27

    Nov

  • 19

    Dec

SAGE Sage Therapeutics
$126.62

-10.64 (-7.75%)

10/17/18
STFL
10/17/18
NO CHANGE
Target $239
STFL
Buy
Stifel confident in approval of Sage Therapeutics' brexanolone ahead of AdComm
Ahead of an FDA advisory committee meeting on Nov 2 to review brexanolone, Stifel analyst Paul Matteis said he is confident in FDA approval and expects the debate on the drug to be centered on labeling, REMS and necessary monitoring requirements. While noting that brexanolone comprises a minority of his Sage valuation, Matteis said the most important thing for the stock is that the panel is both positive and doesn't raise any sort of issue that would read negatively onto SAGE-217, which comprises the majority of his Sage valuation. He maintains a Buy rating and $239 price target on Sage Therapeutics shares.
10/31/18
BMOC
10/31/18
NO CHANGE
Target $203
BMOC
Outperform
BMO sees approval for Sage after Zulresso briefing docs
The FDA this morning released briefing documents for Friday's panel meeting to discuss Sage Therapeutics' Zulresso to treat postpartum depression. It appears the FDA is satisfied with the drug's efficacy and overall tolerability and recognizes a significant unmet need for postpartum depression, BMO Capital analyst Gary Nachman tells investors in a research note. He believes Zulresso will likely be approved on the December 19 FDA action date. Nachman adds, however, that there are some questions on the recommended dosing, since initially the lower dose appears more effective but the doses start to separate during titration when going out beyond 24 hours. He has an Outperform rating on Sage Therapeutics with a $203 price target. The stock in early trading is up 1% to $122.47.
10/31/18
10/31/18
NO CHANGE
Target $206

Overweight
Sage briefing docs 'clearly supportive of approval,' says Piper Jaffray
In a midday research note partially titled "Nothing Too Spooky in Brex Briefing Docs," Piper Jaffray analyst Danielle Brill says this morning's FDA's briefing documents for Sage Therapeutics' brexanolone were overall supportive of approval for postpartum depression. The agency appears comfortable with brexanolone's efficacy, and focused on recommended dosing as a key topic of discussion, Brill writes in a note to investors. The major safety concern, loss of consciousness during infusion which occurred in 4% of women treated, does not appear to be barring of approval, says the analyst. However, Brill adds that while she views the tone of the docs as "clearly supportive of approval," prohibiting administration "at-home" has "obvious negative implications for commercial potential." She has an Overweight rating on Sage Therapeutics with a $206 price target. The stock in midday trading is up 6%, or $7.77, to $129.00.
11/01/18
ADAM
11/01/18
NO CHANGE
Target $220
ADAM
Buy
Sage Therapeutics FDA briefing documents read 'ok,' says Canaccord
Canaccord analyst Sumant Kulkarni noted the FDA posted its briefing documents related to Sage Therapeutics' brexanolone ahead of the advisory committee meeting on the product scheduled for November 2. The analyst said they appear "ok" and said the drug could be the first approved for the treatment of post-partum depression. The analyst said with the stock down roughly 10% since the FDA confirmed the date of the AdCom meeting, he is telling investors to buy the shares. Kulkarni reiterated his Buy rating and $220 price target on Sage Therapeutics shares.

TODAY'S FREE FLY STORIES

CXO

Concho Resources

$103.69

-8.68 (-7.72%)

18:37
02/21/19
02/21
18:37
02/21/19
18:37
Recommendations
Concho Resources analyst commentary  »

Concho Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 28

    May

KHC

Kraft Heinz

$48.19

-0.05 (-0.10%)

18:37
02/21/19
02/21
18:37
02/21/19
18:37
Hot Stocks
Kraft Heinz confirms quarterly dividend cut to 40c from 62.5c per share »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

KHC

Kraft Heinz

$48.19

-0.05 (-0.10%)

18:32
02/21/19
02/21
18:32
02/21/19
18:32
Hot Stocks
Kraft Heinz says has taken 'remedial measures' on procurement issues »

Says write down reflected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

CZR

Caesars

$9.42

-0.21 (-2.18%)

18:25
02/21/19
02/21
18:25
02/21/19
18:25
Hot Stocks
Breaking Hot Stocks news story on Caesars »

Caesars: Las Vegas FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

RARE

Ultragenyx

$58.16

-2.33 (-3.85%)

18:20
02/21/19
02/21
18:20
02/21/19
18:20
Initiation
Ultragenyx initiated  »

Ultragenyx resumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$0.00

(0.00%)

, CPB

Campbell Soup

$35.44

0.26 (0.74%)

18:13
02/21/19
02/21
18:13
02/21/19
18:13
Periodicals
Third Point says confident in Nestle CEO's leadership, Reuters reports »

Third Point told…

NSRGY

Nestle

$0.00

(0.00%)

CPB

Campbell Soup

$35.44

0.26 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    May

STMP

Stamps.com

$198.08

-4.03 (-1.99%)

18:11
02/21/19
02/21
18:11
02/21/19
18:11
Hot Stocks
Breaking Hot Stocks news story on Stamps.com »

Stamps.com drops 50%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

STMP

Stamps.com

$198.08

-4.03 (-1.99%)

18:09
02/21/19
02/21
18:09
02/21/19
18:09
Hot Stocks
Stamps.com to discontinue partnership with USPS »

On its Q4 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

CZR

Caesars

$9.42

-0.21 (-2.18%)

18:08
02/21/19
02/21
18:08
02/21/19
18:08
Hot Stocks
Caesars expect modest Las Vegas revenue growth in Q1 »

Sees adverse weather…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

CZR

Caesars

$9.42

-0.21 (-2.18%)

18:06
02/21/19
02/21
18:06
02/21/19
18:06
Hot Stocks
Breaking Hot Stocks news story on Caesars »

Caesars says will not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

LNT

Alliant Energy

$45.63

0.45 (1.00%)

18:03
02/21/19
02/21
18:03
02/21/19
18:03
Earnings
Breaking Earnings news story on Alliant Energy »

Alliant Energy sees FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

LNT

Alliant Energy

$45.63

0.45 (1.00%)

18:02
02/21/19
02/21
18:02
02/21/19
18:02
Earnings
Alliant Energy reports Q4 EPS 36c, conseensus 35c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

BVN

Buenaventura

$16.53

-0.37 (-2.19%)

17:59
02/21/19
02/21
17:59
02/21/19
17:59
Earnings
Buenaventura reports Q4 EPS (29c), consensus 5c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 12

    Mar

  • 12

    Mar

KHC

Kraft Heinz

$48.19

-0.05 (-0.10%)

17:58
02/21/19
02/21
17:58
02/21/19
17:58
Hot Stocks
Kraft Heinz says expects to face profit headwinds in 2019 »

Says: Expects EBITDA down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

GABC

German American Bancorp

$31.59

(0.00%)

, CZFC

Citizens First

$23.30

1.87 (8.73%)

17:56
02/21/19
02/21
17:56
02/21/19
17:56
Hot Stocks
German American, Citizens First announce merger pact »

German American Bancorp,…

GABC

German American Bancorp

$31.59

(0.00%)

CZFC

Citizens First

$23.30

1.87 (8.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$291.18

-11.33 (-3.75%)

17:56
02/21/19
02/21
17:56
02/21/19
17:56
Periodicals
Lucid Motors is 'working' on an all electric SUV, Verge says »

Electric vehicle startup…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 18

    Mar

  • 19

    Mar

CZR

Caesars

$9.42

-0.21 (-2.18%)

17:54
02/21/19
02/21
17:54
02/21/19
17:54
Hot Stocks
Caesars sees FY19 same-store capex $375M-$450M »

Sees FY19 development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

PBA

Pembina Pipeline

$36.44

-0.235 (-0.64%)

17:54
02/21/19
02/21
17:54
02/21/19
17:54
Earnings
Pembina Pipeline reports Q4 EPS C$0.66 vs C$0.83 last year »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

KHC

Kraft Heinz

$48.19

-0.05 (-0.10%)

17:53
02/21/19
02/21
17:53
02/21/19
17:53
Hot Stocks
Kraft Heinz continues to fall, now down 16.5% to $40.25 »

In after-hours trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

CZR

Caesars

$9.42

-0.21 (-2.18%)

17:52
02/21/19
02/21
17:52
02/21/19
17:52
Hot Stocks
Caesars says in discussions with Carl Icahn after his disclosed stake »

Comments from Q4 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

HRS

Harris

$164.55

-0.62 (-0.38%)

17:48
02/21/19
02/21
17:48
02/21/19
17:48
Hot Stocks
Harris awarded $168.8M Navy contract modification »

Harris has been awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KHC

Kraft Heinz

$48.19

-0.05 (-0.10%)

17:45
02/21/19
02/21
17:45
02/21/19
17:45
Hot Stocks
Kraft Heinz to cut quarterly dividend to 40c from 62.5c per share »

Says: Higher supply chain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

HON

Honeywell

$152.60

-1.2 (-0.78%)

17:43
02/21/19
02/21
17:43
02/21/19
17:43
Hot Stocks
Honeywell awarded not-to-exceed $150M Air Force contract for ATTAM Phase 1 »

Honeywell has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

BA

Boeing

$417.48

-4.13 (-0.98%)

17:40
02/21/19
02/21
17:40
02/21/19
17:40
Hot Stocks
Tapestry awarded not-to-exceed $259M Air Force contract for WPS »

Tapestry Solutions, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

  • 28

    May

INFN

Infinera

$4.87

-0.02 (-0.41%)

17:39
02/21/19
02/21
17:39
02/21/19
17:39
Earnings
Infinera sees Q1 EPS (27c) plus/minus 2c, consensus (19c) »

Sees Q1 GAAP revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.